Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.
Medicine (Baltimore)
; 103(4): e36214, 2024 Jan 26.
Article
em En
| MEDLINE
| ID: mdl-38277579
ABSTRACT
RATIONALE Radical surgery offers the best chance of cure, it is critical to expand surgery opportunities for patients with early-stage lung cancer to prolong overall survival. However, evidence is still limited regarding the application of neoadjuvant therapy with EGFR-tyrosine kinase. PATIENT The patient reported here was a 53-year-old woman with right lower lung adenosquamous carcinoma. DIAGNOSES The lung cancer was staged as T3N1M0. Tumor genotype disclosed EGFR Exon19 c.2235-2249de p.E746-A750del. INTERVENTION After neoadjuvant treatment with icotinib, she underwent thoracotomy and achieved pathological complete response. OUTCOMES:
She is currently receiving adjuvant icotinib therapy without recurrence or metastasis during 18-month follow-up. LESSONS Our case indicated that the feasibility of neoadjuvant icotinib in EGFR-mutant lung adenosquamous carcinoma.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinazolinas
/
Carcinoma Adenoescamoso
/
Carcinoma Pulmonar de Células não Pequenas
/
Éteres de Coroa
/
Neoplasias Pulmonares
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Medicine (Baltimore)
Ano de publicação:
2024
Tipo de documento:
Article